Earnings Overview: Teva Pharmaceutical Industries Surpasses Q3 Expectations and Raises FY Outlook Above Projections
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 05 2025
0mins
Source: SeekingAlpha
Teva vs. Viatris: The competition between Teva Pharmaceutical and Viatris is highlighted, focusing on their potential dominance in the pharmaceutical market under President Trump's administration.
Turnaround Potential: Teva is experiencing a turnaround driven by a promising pipeline, indicating potential growth and investment opportunities.
Pipeline Momentum: The momentum in Teva's pipeline suggests a new era for investors, with expectations of increased product offerings and market presence.
Q3 Financial Performance: Teva reported a strong Q3 performance, with a non-GAAP EPS of $0.78, exceeding expectations, and revenue of $4.48 billion, surpassing forecasts by $150 million.
Analyst Views on TEVA
Wall Street analysts forecast TEVA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TEVA is 35.71 USD with a low forecast of 29.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
10 Buy
1 Hold
0 Sell
Strong Buy
Current: 31.660
Low
29.00
Averages
35.71
High
40.00
Current: 31.660
Low
29.00
Averages
35.71
High
40.00
About TEVA
Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
